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Introduction . Bilateral breast cancer (BBC) consists of 2–12% all cases of breast carcinoma. In relation to time between 
the first and second cancer diagnosis, the synchronous (s-BBC) or metachronous (m-BBC) bilateral breast cancer is 
defined.
Material and methods . The clinicopathologic characteristics of 303 patients treated between 1963 and 2014 for 
bilateral breast cancer was presented. Synchronous BBC was diagnosed in 70 patients (23.1%) and remaining 233 
patients (76.9%) developed metachronous BBC.
Patients with m-BBC in comparison to s-BBC were younger (mean age: 51.4 vs 60.6 years), the positive family cancer 
history was rare (36.7% vs 48.5%), and more frequently these patients were before menopause (65.7% vs 44.3%). While 
the lobular type of breast cancer which consisted of 6.6% cases in first breast and 8.9% cases of second carcinomas, 
more frequently was presented in s-BBC (8.6%) in comparison to m-BBC (6%).
Results . The mean time of follow up was 174 months. The 5- and 10-year overall survival rates were 89.3% and 76.1%, 
respectively. The presence of s-BBC connected with worse prognosis; the 5- and 10-year overall survival were 93.1% 
and 82% for m-BBC and 76.4% and 52.1% for s-BBC (p = 0.00244, log-rank test).
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Introduction
The incidence of bilateral breast cancer affects 2–12% of 
all breast cancer patients. The risk of developing cancer in 
the second breast is greater than the risk of developing the 
original disease in a hitherto healthy person. It is estimated 
that each year 0.7% of patients with breast cancer develop 
cancer in their second breast [1–3].
The development of two separate primary breast can-
cers is the result of genetic predisposition, exposure to 
specific environmental factors or a combination of inde-
pendent events [4].
The risk factors for bilateral breast cancer (BBC) include 
family history of malignant neoplasms, development of 
breast cancer at an early age, lobular breast cancer, early 
stage of development, presence of receptor expression and 
the type of treatment methods used [5–9].
Depending on the time between the diagnosis of BBC 
in both breasts, synchronous and metachronous bilateral 
breast cancer can be distinguished [10, 11]. The diagnosis of 
cancer in both breasts at the same time does not raise any 
doubts that it is synchronous BBC. However, if the diagnosis 
of cancer in the second breast takes place after some time 
since the diagnosis of the first tumor, there is currently no 
clear time milestone to determine whether it is a synchro-
nous or metachronous disease. The literature data indicate 
that researchers use the period from 1 month to 1 year as 
the boundary between classification into synchronous or 
metachronous BBC [5, 12].
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The aim of this paper is to present the characteristics of 
a group of patients with bilateral breast cancer, in relation to 
the time between the diagnosis of breast cancer (synchro-
nous vs metachronous BBC).
Material and methods
Synchronous bilateral breast cancer (s-BBC) was defined 
as the diagnosis of breast cancer at the same time or up to 
6 months, while metachronous bilateral breast cancer (m-
-BBC) refers to those cases of second breast cancer that were 
diagnosed after a period longer than 6 months.
Patients
In 303 breast cancer patients treated in the years 1963–
2014 in the Maria Skłodowska-Curie Institute — Oncology 
Center, Branch in Kraków, bilateral breast cancer was dia-
gnosed. These patients were: 0.25% of all (121 209) patients, 
1.5% of all (20 004) breast cancer patients and 9.4% of all 
(3219) multiple cancer patients treated during this period.
The age of patients included in the analysis was on 
average 53.5 years (range: 19–85 years). Of all patients with 
bilateral breast cancer, 70 (23.1%) had synchronous and 233 
(76.9%) had metachronous BBC.
The time between the diagnosis of cancer in both bre-
asts ranged from 0 to 543 months and was 85 months on 
average. Figure 1 shows the frequency of diagnosis of se-
cond breast cancer depending on the interval between 
cases (s-BBC vs m-BBC).
The range and mean time between the diagnosis of both 
cancers depending on the type of BBC was 0–5 months and 
0.5 months (in the case of s-BBC) and 7–543 months and 94 
months (in the case of m-BBC), respectively.
Tables I and II present the characteristics and methods 
of treatment applied in the whole group and in relation to 
the type of bilateral breast cancer.
Family history of cancer was found in 117 (38.6%) pa-
tients. Women before menopause (184 — 60.7%), T1–2 
cancer (78.9% in the first and 91.4% in the second breast 
cancer) and less frequent lymphadenopathy (69.3% in the 
second disease) dominated in the analyzed group. Surgi-
cal treatment with mastectomy dominated in all patients 
(88.4% in the first and 70.3% in the second breast cancer). 
In 170 patients (55.7%) radiotherapy was performed — in 
35% on one side and in 21.1% on both sides. Adjuvant 
chemotherapy was applied in 169 patients (55.8%) and 
hormone therapy in 210 patients (69.3%).
Comparison of m-BBC and s-BBC subgroups shows 
significant differences in age, family history, menopause, 
histological type of breast cancer, frequency of lymph node 
metastases and treatment methods used (surgery, hormone 
therapy). In the case of m-BBC, compared to s-BBC, patients 
were younger (mean age: 51.4 years vs 60.6 years), less 
frequent was family history of cancer (36.7% vs 48.5%), 
more often were before menopause (65.7% vs 44.3%). In 
contrast, lobular breast cancer represented 6.6% of first and 
8.9% of second breast cancers and was significantly more 
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Figure 1 . Bilateral breast cancer frequency depending on the time between the first breast cancer diagnosis and the cancer diagnosis in the 
second breast
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common in s-BBC (8.6%) compared to m-BBC (6%) in the 
first breast cancer. Surgical procedures with breast saving 
were more frequent in the treatment of the second breast 
(29.7% vs 11.6%), especially visible differences concerned m-
-BBC (7.3% in the first breast vs 25.8% in the second breast).
Statistical methods
The criterion for results evaluation in the whole group 
and in relation to the type of bilateral breast cancer (s-BBCvs 
m-BBC) was adopted for 5- and 10-year survival rates esti-
mated with the Kaplan-Meier method, and the results were 
compared with the log-rank test. In comparison of s-BBC and 
m-BBC groups the chi2 test (step values) or variance analysis 
(continuous values) were applied. All statistical analyses 
were carried out using Statistica v.13.3 TIBCO Software Inc. 
package, assuming a significance level of p ≤ 0.05.
Results
In the analyzed group the observation time (calculated 
from the diagnosis of cancer in the second breast) was 2–558 
months (mean: 174.3 months, median: 159 months). At that 
time 160 patients (52.8%) died of: breast cancer (66 patients 
— 21.8%), other cancer (5 patients — 1.7%), non-cancer 
diseases (82 patients — 27.1%).
Figure 2 shows the survival probability curves for the 
whole group (a) and depending on the type of BBC (b).
Table I . Characteristics of a group of 303 patients treated for bilateral breast cancer (BBC)
Factor
 n = 303
Whole group m-BBC* s-BBC** p
n = 233 n = 70
Age (mean ± SD) 53.3 ± 12.3 51.4 ± 11.2 60.6 ± 13.1 < 0.00001
Family history:
negative 186 (61.4%) 150 (64.4%) 36 (51.4%)
breast cancer 55 (18.2%) 43 (18.5%) 12 (17.1%) 0.03220
other cancer 62 (20.5%) 40 (17.2%) 22 (31.4%)
Menopause
no 184 (60.7%) 153 (65.7%) 31 (44.3%)
yes 119 (39.3%) 80 (34.3%) 39 (55.7%) 0.00132
Histopathological type
– first breast cancer:
ductal 219 (72.3%) 162 (69.5%) 57 (81.4%)
lobular 20 (6.6%) 14 (6%) 6 (8.6%) 0.03141
other 64 (21.1%) 57 (24.5%) 7 (10%)
– second breast cancer
ductal 237 (78.2%) 184 (79%) 53 (75.7%)
lobular 27 (8.9%) 20 (8.6%) 7 (10%) 0.84552
other 39 (12.9%) 29 (12.5%) 10 (14.3%)
T parameter
– first breast cancer
T1–2 239 (78.9%) 278 (76.4%) 61 (87.1%)
T3–4 64 (22.1%) 55 (23.6%) 9 (12.9%) 0.05337
– second breast cancer
T1–2 277 (91.4%) 211 (90.6%) 66 (94.3%)
T3–4 26 (8.6%) 22 (9.4%) 4 (5.7%) 0.32882
pN parameter
– first breast cancer
pN0 150 (49.5%) 112 (48.1%) 38 (54.3%)
pN+ 153 (50.5%) 121 (51.9%) 32 (45.7%) 0.36161
– second breast cancer
pN0 211 (69.3%) 151 (64.8%) 60 (85.7%)
pN+ 92 (30.4%) 82 (35.2%) 10 (14.3%) 0.00085
*m-BBC — metachronous bilateral breast cancer
**s-BBC — synchronous bilateral breast cancer
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The percentage of 5- and 10-year total survival in the 
whole group was 89.3% and 76.1%, respectively, while in 
relation to the analysed subgroups m-BBC and s-BBC were 
as follows: 93.1% and 76.4% (5-year-old) and 82% and 52.1% 
(10-year); these differences were statistically significant 
(p = 0.00244, log-rank test).
During the follow-up 47 patients (15.5%) had a relapse, 
which was most often located on the chest wall or in the 
breast (85.1%). In 78 patients (25.7%) the development of 
distant metastases was observed, the most frequent loca-
lization of which were bones (60.3%).
Table III summarizes the treatment failures that occurred 
in patients with bilateral breast cancer.
In the s-BBC subgroup, in comparison with the m-BBC, 
the development of distant metastases took place signifi-
cantly earlier (mean time of development: 59.2 months vs 
114.2 months).
Discussion
In the material presented, bilateral breast cancer (BBC) 
affected 1.5% of all patients with breast cancer, 23.1% of 
whom synchronous BBC was diagnosed and 76.9% of pa-
tients with metachronous BBC. The frequency of these ty-
pes of bilateral breast cancer presented in the literature is 
30–48% for s-BBC and 52–70% for m-BBC [1, 11, 13–15].
In the case of bilateral breast cancer, the two primary 
cancers located in both breasts may develop simultaneously 
or after a period of time. This development may be the result 
of genetic predisposition, exposure to environmental factors 
or the co-participation of two independent events. The 
development of s-BBC, which resembles unilateral breast 
cancer, indicates an accumulation of the effects of exposure 
to environmental carcinogens, while the high risk of m-BBC 
development in young women indicates the role of genetic 
predisposition [13, 14, 16].
Table II . Treatment methods used in 303 patients with bilateral breast cancer (BBC)
Factor Whole group m-BBC* s-BBC** p
n = 303 n = 233 n = 70
Surgery 303 (100%) 233 (100%) 70 (100%)
– first breast cancer
BCS 35 (11.6%) 17 (7.3%) 18 (25.7%)
mastectomy 268 (88.4%) 216 (92.7%) 52 (74.3%) 0.00002
– second breast cancer
BCS 90 (29.7%) 60 (25.8%) 30 (42.9%)
mastectomy 213 (70.3%) 173 (74.3%) 40 (57.1%) 0.00602
Radiotherapy
none 133 (44.3%) 104 (44.6%) 29 (41.4%)
unilateral 106 (35%) 86 (36.9%) 20 (28.6%) 0.10063
bilateral 64 (21.1%) 43 (18.5%) 21 (30%)
Chemotherapy 169 (55.8%) 131 (56.2%) 38 (54.3%) 0.77472
Hormone therapy 210 (69.3%) 152 (65.2%) 58 (82.9%) 0.00506
Tamoxifen 197 (65%) 140 (60.1%) 57 (81.4%) 0.00103
*m-BBC — metachronous bilateral breast cancer 
**s-BBC — synchronous bilateral breast cancer
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Figure 2 . Probability of overall survival (a) in the whole group and (b) 
in depending on the type of bilateral breast cancer (metachronous vs 
synchronous)
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One of the factors conducive to the development of BBC 
is family history of cancer [8, 12, 17–21]. In the presented 
material 38.7% of patients were diagnosed with cancer in 
the family, which significantly more often concerned pa-
tients with s-BBC than patients with m-BBC (48.5% vs 35.7%).
Other authors indicate that despite the relationship betwe-
en family history of cancer and development of BBC, only 5% 
of patients with BBC are diagnosed with BRCA1/BRCA2 gene 
mutations [8]. Moreover, there are data in the literature which 
do not confirm the correlation between the family history of 
cancer and the development of bilateral breast cancer [22, 23].
Our own observations indicate that BBC was more fre-
quent in premenopausal patients (60.7% vs 39.3%), and 
after taking into account the type of BBC, s-BBC was more 
frequent in postmenopausal patients (55.7%), while m-BBC 
was more frequent in premenopausal patients (65.7%). The 
dependence of s-BBC on age is also confirmed by differen-
ces in mean age, which indicate that patients with s-BBC 
are older than those with m-BBC (60.6 years vs 51.4 years). 
Different observations were published by Hartman et al., 
who found that older women were more often diagnosed 
with m-BBC [12]. However, it should be noted that in the 
categorisation of synchronous — metachronous BBC the 
authors have adopted a period of 3 months.
Others, such as Intra et al. [23] and Wadasadawala et 
al. [20], found that s-BBC occurred in older patients after 
menopause and was more often associated with lobular 
breast cancer. Similar observations are made by the au-
thors: lobular carcinoma was significantly more frequent in 
patients with s-BBC and this referred both the first (8.6% vs 
6%) and the second (10% vs 8.6%) breast cancer.
Literature data indicate that s-BBC in comparison to 
m-BBC is characterized by worse prognosis [3, 5, 7, 12–14, 
16, 20, 21, 24–30]. In the material presented by Ibrahim et 
al. [14], the percentage of 5-year experiences for s-BBC and 
m-BBC is 60% and 78.7%, respectively. The results by Vuota 
et al. are similar: [5]: 63.3% (s-BBC) and 94.6% (m-BBC). In 
the material presented by Heron et al., in turn, [7] this per-
centage is: 83.1% (s-BBC) and 97.8% (m-BBC). Sim et al. [21] 
point out that although s-BBC is a more favourable type of 
breast cancer in terms of prognosis (the presence of hormo-
nal receptor expression and lack of HER-1 expression), it is 
nevertheless associated with significantly worse prognosis 
compared to m-BBC, which is explained by the existence of 
additional biological and genetic factors.
According to Barreta et al. [24] this is associated with 
a more frequent lack of hormonal receptor expression in 
patients with s-BBC, which is a recognized negative progno-
stic factor. Moreover, the authors point out that the change 
of receptor status (from the presence of expression to the 
lack of expression) in the case of m-BBC is an independent 
predictive factor [24].
Our own results confirm that s-BBC, compared to m-BBC, 
is associated with worse prognosis. The percentage of 5-year 
Table III. Treatment failures in patients with bilateral breast cancer (BBC)
Factor Whole group m-BBC* s-BBC** p
n = 303 n = 233 n = 70
Relapse 47 (15.5%) 38 (16.3%) 9 (12.9%) 0.48419
Average development time (months) 47.9 49.1 42.8 0.76582
Location:
chest wall/breast 40 (85.1%) 32 (82.1%) 8 (88.9%)
lymph nodes 5 (10.6%) 4 (10.3%) 1 (11.1%) 0.69127
chest wall/breast + lymph nodes 2 (4.3%) 2 (5.1%) –
Distant metastases 78 (25.7%) 56 (24%) 22 (31.4%) 0.21468
Average development time (months) 98.7 114.2 59.2 0.00001
Location: 
bones 47 (60.3%) 33 (58.9%) 14 (63.6%)
lymph nodes 14 (17.9%) 12 (21.4%) 2 (9.1%)
lungs 12 (15.4%) 9 (16.1%) 3 (13.6%) 0.58033
liver 12 (15.4%) 6 (10.7%) 6 (27.3%)
brain 11 (14.1%) 9 (16.1%) 2 (9.1%)
skin 1 (1.3%) 1 (1.8%) –
peritoneum 1 (1.3%) 1 (1.8%) –
Other cancer 33 (10.9%) 28 (12%) 5 (7%) 0.25099
Average development time (months) 133.7 151.4 34.4 0.00008
*m-BBC — metachronous bilateral breast cancer 
**s-BBC — synchronous bilateral breast cancer
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survival was: 76.4% vs 93.1% respectively. Moreover, the 
development of distant metastases was observed in patients 
with s-BBC significantly earlier than in patients with m-BBC.
Summary
Our own observations and literature data indicate that 
although bilateral breast cancer is relatively rare, given the 
incidence of breast cancer and the associated risk of de-
veloping breast cancer in the other breast, it should be 
borne in mind and taken into account during diagnostics 
and post-treatment follow-up. Diagnosis of synchronous 
bilateral breast cancer is a prognostic factor influencing 
the deterioration of prognosis in breast cancer patients, 
whereas the occurrence of long-term risk of metachronistic 
development of bilateral breast cancer indicates the need 
for careful clinical follow-up and the role of mammographic 
screening in patients with diagnosed breast cancer.
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